KalVista Pharmaceuticals (KALV) Research & Development (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Research & Development data on file, last reported at $15.2 million in Q3 2025.

• For the quarter ending Q3 2025, Research & Development fell 43.03% year-over-year to $15.2 million; the trailing twelve-month figure through Jul 2025 stood at $74.3 million (down 20.54% YoY), and the FY2025 full-year result was $71.7 million, down 16.78% from the prior year.
• Research & Development slipped to $15.2 million in Q3 2025, from $15.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $26.6 million in Q3 2024 to a low of $9.1 million in Q1 2021.
• A 5-year average of $18.4 million and a median of $18.6 million in 2022 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 116.97% in 2022 and plunged 43.03% in 2025, its largest moves.
• Tracing KALV's Research & Development over 5 years: stood at $17.5 million in 2021, then climbed by 3.03% to $18.1 million in 2022, then advanced by 5.6% to $19.1 million in 2023, then retreated by 12.99% to $16.6 million in 2024, then decreased by 8.72% to $15.2 million in 2025.
• Business Quant data shows KALV's Research & Development at $15.2 million in Q3 2025, $15.9 million in Q2 2025, and $16.6 million in Q4 2024.